| Bioactivity | TNG908 is a MTAP-cooperative PRMT5 inhibitor that can pass through the blood-brain barrier. TNG908 is 15 times more selective for MTAP null cell lines than MTAPWT cell lines, and can be used in cancer research[1]. | ||||||||||||
| Name | TNG908 | ||||||||||||
| CAS | 2760481-53-4 | ||||||||||||
| Formula | C21H23N5O2S | ||||||||||||
| Molar Mass | 409.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. K. Briggs, et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer.MOLECULAR TARGETED AGENTS 2| VOLUME 174, SUPPLEMENT 1, S84, OCTOBER 2022. |